Stock Screener App

Frei -

Installieren

Drug Manufacturers - Major

70.08

0.34% -0.24

Vorhandelsmarkt: 70.00 -0.08 -0.11%

Astrazeneca PLC (AZN)

Überblick Nachrichten Preisverlauf Optionskette Warum fällt AZN? Forum Prognose Aktiensplit Dividendenhistorie

Astrazeneca PLC Aktie (AZN) Neueste Nachrichten

AstraZeneca Loses Bid To Revive Patent For Diabetes Drug - Law360

JPMorgan Goes Global With HOLA ETF—Stocks Plus Built‑In Crash Protection - Benzinga

AstraZeneca’s SERENA-6 Trial: A Potential Game-Changer in Breast Cancer Treatment - TipRanks

AstraZeneca’s New CAR T Therapy Study: A Potential Game-Changer for Refractory SLE - TipRanks

AstraZeneca’s Phase 3 COPD Study: Key Insights for Investors - TipRanks

AstraZeneca’s Promising Phase II Study on AZD7798 for Crohn’s Disease - TipRanks

AstraZeneca’s Benralizumab Trial: A Potential Game-Changer for Pediatric Eosinophilic Diseases - TipRanks

AstraZeneca’s New Study on AZD4954: A Potential Game Changer in Cardiovascular Treatment - TipRanks

AstraZeneca’s Ravulizumab Study: A New Hope for gMG Patients - TipRanks

AstraZeneca rare disease drug fails key trial tests - BioPharma Dive

AstraZeneca’s AZD5004 Study: A New Hope for Type 2 Diabetes Treatment? - TipRanks

AstraZeneca’s Real-World Study on Dapagliflozin: A Potential Game-Changer for Heart Failure Treatment - TipRanks

AstraZeneca’s TROPION-Lung15 Study: A New Hope for Advanced Lung Cancer? - TipRanks

AstraZeneca’s New Obesity Drug: A Potential Game-Changer? - TipRanks

AstraZeneca’s CASPIAN Study: Promising Advances in Lung Cancer Treatment - TipRanks

AstraZeneca’s New Study Targets COPD Burden in Egypt: What Investors Need to Know - The Globe and Mail

AstraZeneca's Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition - inkl

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist - insights.citeline.com

AstraZeneca reports Phase III trial of anselamimab did not meet primary goal - Investing.com India

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewswire Inc.

AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study - MarketScreener

AstraZeneca’s anselamimab treatment fails to meet main trial goal; shares slip - Investing.com UK

AstraZeneca shares open lower after rare disease drug fails to meet main trial goal - Proactive Investors

AstraZeneca Rare Disease Drug Disappoints in Advanced Study - Bloomberg.com

AstraZeneca's amyloidosis treatment fails main goal in late-stage study - MarketScreener

AstraZeneca drug fails main goal of late-stage amyloidosis study - Reuters

AstraZeneca: mixed phase III trial results for anselamimab - MarketScreener

AstraZeneca Says Phase 3 Trial for Amyloidosis Medication Fails to Meet Primary Endpoint - MarketScreener

AstraZeneca’s Real-world COPD Study: Market Implications of BGF Analysis - TipRanks

AstraZeneca’s Benralizumab Study: A Potential Game-Changer for Severe Asthma - TipRanks

AstraZeneca’s INTERSTELLAR Study: Real-World Insights into Anifrolumab for SLE - TipRanks

Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance

AstraZeneca PLC (AZN) Secures EU Approval for Imfinzi - Insider Monkey

AstraZeneca Meets All Key Goals in Phase III Hypertension Study - Nasdaq

AstraZeneca’s Observational Study on SLE in Russia: Key Insights for Investors - TipRanks

Barclays: AstraZeneca's Q2 Results to Demonstrate 'Resilience' Amid Headwinds - MarketScreener

AstraZeneca’s Phase III Study on Baxdrostat and Dapagliflozin: A Potential Breakthrough in CKD Treatment - TipRanks

AstraZeneca (LSE:AZN) Unveils Promising Phase III Results For Baxdrostat In Hypertension Trial - Yahoo Finance

AstraZeneca’s NeoCOAST-2 Study: A New Horizon in Lung Cancer Treatment - TipRanks

AstraZeneca’s Latest Clinical Study on NSCLC: Key Insights for Investors - TipRanks

AstraZeneca’s ARTEMIDE-Lung03: A Promising Phase III Study in Lung Cancer Treatment - TipRanks

AstraZeneca’s Anifrolumab Study: Promising Results for SLE Treatment - TipRanks

AstraZeneca’s Phase II Study on AZD4604: A Potential Breakthrough in Asthma Treatment - TipRanks

AstraZeneca blood pressure drug succeeds in late-stage trial - BioPharma Dive

AstraZeneca’s New Study on TDC Regimen: Implications for NSCLC Treatment and Market Impact - TipRanks

AstraZeneca reports positive Phase III results for baxdrostat in hypertension - Investing.com

AstraZeneca’s Baxdrostat hits all Phase III endpoints, eyes 2025 filing | AZN SEC FilingForm 6-K - Stock Titan

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat - insights.citeline.com

Here's Why Astrazeneca (AZN) is a Strong Value Stock - Yahoo Finance

AstraZeneca's baxdrostat meets key goals in late-stage trial for hypertension - Seeking Alpha

AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial - Benzinga

Astrazeneca's Phase 3 Trial of Baxdrostat in Hypertension Meets Primary, Secondary Endpoints - MarketScreener

AstraZeneca gains on successful trial for blood pressure drug, 14 Jul 2025 11:30 - Shares Magazine

Trending tickers: The latest investor updates on Lionsgate, Nio, Boeing, AstraZeneca and Fresnillo - Yahoo

AstraZeneca drug lowers high blood pressure in late-stage study; shares rise - MarketScreener

Astra says potential blockbuster reduced high blood pressure - Moneycontrol

Astra Says Potential Blockbuster Reduced High Blood Pressure - Bloomberg.com

AstraZeneca says potential blockbuster reduced high blood pressure - The Edge Malaysia

AstraZeneca: conclusive results against hypertension - MarketScreener

AstraZeneca shares gain after drug shows success in late-stage hypertension trial - Investing.com UK

AstraZeneca drug lowers high BP in late-stage study; shares rise - MarketScreener

AstraZeneca drug meets all goals in high blood pressure study - MarketScreener

AstraZeneca says baxdrostat met primary and secondary endpoints in Phase III trial - MarketScreener

AstraZeneca's Baxdrostat Meets Phase III Endpoints In Hypertension Trial - DirectorsTalk Interviews

An AstraZeneca Exit Wouldn’t Doom London - Bloomberg.com

AstraZeneca Stock Rises As Experimental Drug Lowers Blood Pressure In Late-Stage Study, Retail’s Yet To React - Stocktwits

AstraZeneca - Britannica

AstraZeneca’s New Study on CKD Treatment: Potential Market Impacts - The Globe and Mail

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters